Bioequivalence Study of Fixed-Dose Combination of Bempedoic Acid, Ezetimibe, and Rosuvastatin Versus Individual Tablets in Healthy Subjects

The primary objective of this study is to evaluate the **bioequivalence** of a fixed-dose combination tablet compared to individual tablets of **bempedoic acid**, **ezetimibe**, and **rosuvastatin**. This assessment is clinically relevant as it determines whether the combination tablet can be used interchangeably with the individual tablets, potentially improving patient adherence and simplifying treatment regimens. No secondary objectives are specified for this study.

The clinical trial involves a **study population** that includes both male and female participants, with an **age range** of 18 to 65 years. The trial does not focus on individuals with any specific **medical condition**, as it is designed for a general healthy population. The total number of participants has not been disclosed by the sponsor. The selection process for the trial population is not specified, but it includes a **vulnerable population**. There are no specific lifestyle considerations such as diet, physical activity, or habits mentioned for this study. Key inclusion or exclusion criteria have not been provided.

The clinical trial is designed to evaluate the **bioequivalence** of a fixed-dose combination of Bempedoic Acid, Ezetimibe, and Rosuvastatin compared to the individual administration of these tablets. This study is a Phase 2 trial, which is categorized as a randomized, double-blind, controlled trial. The estimated duration of the trial is from September 1, 2025, to November 25, 2025. Participants will be involved in the study for the entire duration unless early termination criteria are met.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status, adherence to the study protocol, and any adverse events. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the primary and secondary endpoints.

Participant involvement is expected to last until the end of the trial period, unless specific conditions necessitate early withdrawal. These conditions may include significant adverse reactions, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on September 1, 2025, with an estimated completion date of November 25, 2025. The efficacy assessment will focus on specific endpoints, although these are not detailed in the provided data. The trial will follow a structured timeline to evaluate the treatment's impact, but specific methods and tools for measuring efficacy are not specified. The trial's objective is to gather data on the treatment's effectiveness within the defined period, contributing to the understanding of its potential benefits in the targeted medical condition.